Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Emerald Bioscience

OTCPK:EMBI
Snowflake Description

Slightly overvalued with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EMBI
OTCPK
$13M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for unmet medical needs worldwide. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Emerald Bioscience has significant price volatility in the past 3 months.
EMBI Share Price and Events
7 Day Returns
-12.3%
OTCPK:EMBI
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-89.7%
OTCPK:EMBI
0%
US Biotechs
-11.5%
US Market
EMBI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Emerald Bioscience (EMBI) -12.3% -25.1% -50% -89.7% -77.1% -98.6%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • EMBI underperformed the Biotechs industry which returned 0% over the past year.
  • EMBI underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
EMBI
Industry
5yr Volatility vs Market

Value

 Is Emerald Bioscience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Emerald Bioscience. This is due to cash flow or dividend data being unavailable. The share price is $0.071.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Emerald Bioscience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Emerald Bioscience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:EMBI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.01
OTCPK:EMBI Share Price ** OTCPK (2020-03-27) in USD $0.07
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Emerald Bioscience.

OTCPK:EMBI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:EMBI Share Price ÷ EPS (both in USD)

= 0.07 ÷ 0.01

9.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Emerald Bioscience is good value based on earnings compared to the US Biotechs industry average.
  • Emerald Bioscience is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Emerald Bioscience's expected growth come at a high price?
Raw Data
OTCPK:EMBI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 9.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Emerald Bioscience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Emerald Bioscience's assets?
Raw Data
OTCPK:EMBI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.00
OTCPK:EMBI Share Price * OTCPK (2020-03-27) in USD $0.07
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
OTCPK:EMBI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:EMBI Share Price ÷ Book Value per Share (both in USD)

= 0.07 ÷ 0.00

23.7x

* Primary Listing of Emerald Bioscience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Emerald Bioscience is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Emerald Bioscience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Emerald Bioscience has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Emerald Bioscience expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Emerald Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Emerald Bioscience expected to grow at an attractive rate?
  • Unable to compare Emerald Bioscience's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Emerald Bioscience's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Emerald Bioscience's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:EMBI Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:EMBI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:EMBI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -6 1
2019-09-30 -6 -10
2019-06-30 -5 -7
2019-03-31 -4 -26
2018-12-31 -4 -19
2018-09-30 -5 -14
2018-06-30 -4 -12
2018-03-31 -4 -10
2017-12-31 -3 -4
2017-09-30 -2 -5
2017-06-30 -2 -5
2017-03-31 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Emerald Bioscience is high growth as no earnings estimate data is available.
  • Unable to determine if Emerald Bioscience is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:EMBI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Emerald Bioscience Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EMBI Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.01
2019-09-30 -0.07
2019-06-30 -0.05
2019-03-31 -0.19
2018-12-31 -0.16
2018-09-30 -0.15
2018-06-30 -0.18
2018-03-31 -0.23
2017-12-31 -0.15
2017-09-30 -0.19
2017-06-30 -0.23
2017-03-31 -0.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Emerald Bioscience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of EMBI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Emerald Bioscience's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Emerald Bioscience's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Emerald Bioscience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Emerald Bioscience has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Emerald Bioscience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Emerald Bioscience's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Emerald Bioscience's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Emerald Bioscience has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Emerald Bioscience has become profitable in the last year making it difficult to compare the US Biotechs industry average.
Earnings and Revenue History
Emerald Bioscience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Emerald Bioscience Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EMBI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.05 4.39 2.24
2019-09-30 -10.02 4.20 1.72
2019-06-30 -7.19 4.19 1.27
2019-03-31 -25.75 4.19 0.58
2018-12-31 -19.19 4.18 0.33
2018-09-30 -13.93 4.45 -0.09
2018-06-30 -12.32 4.15 -0.07
2018-03-31 -10.36 3.74 -0.01
2017-12-31 -4.14 3.80 0.06
2017-09-30 -4.62 3.58 0.20
2017-06-30 -5.09 3.69 0.19
2017-03-31 -3.81 4.04 0.59
2016-12-31 -3.50 3.83 0.64
2016-09-30 -2.75 3.77 0.95
2016-06-30 -2.99 3.91 0.85
2016-03-31 -5.62 4.20 0.43
2015-12-31 -4.84 3.98 0.33
2015-09-30 -5.85 4.82 0.04
2015-06-30 -5.53 4.58 0.25
2015-03-31 -3.61 3.41 0.20
2014-12-31 -2.73 2.56 0.17
2014-09-30 -1.06 0.87 0.19
2014-06-30 -0.23 0.23
2014-03-31 -0.12 0.12
2013-12-31 -0.12 0.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Emerald Bioscience made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Emerald Bioscience used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Emerald Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Emerald Bioscience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Emerald Bioscience has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Emerald Bioscience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Emerald Bioscience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Emerald Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Emerald Bioscience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Emerald Bioscience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Emerald Bioscience Company Filings, last reported 2 months ago.

OTCPK:EMBI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 0.55 0.39 1.83
2019-09-30 -16.40 3.30 1.32
2019-06-30 -11.64 3.10 2.81
2019-03-31 -27.86 2.91 4.41
2018-12-31 -15.56 1.36 1.85
2018-09-30 -10.16 0.00 1.06
2018-06-30 -8.25 0.00 1.87
2018-03-31 -5.75 0.00 2.95
2017-12-31 -0.80 0.24 0.26
2017-09-30 -1.31 0.00 0.04
2017-06-30 -0.70 0.00 0.11
2017-03-31 -0.13 0.00 0.38
2016-12-31 -0.34 0.00 0.06
2016-09-30 -0.15 0.00 0.32
2016-06-30 0.59 0.00 0.83
2016-03-31 1.86 0.00 2.06
2015-12-31 2.93 0.00 3.22
2015-09-30 3.92 0.00 4.34
2015-06-30 -0.86 0.00 0.60
2015-03-31 -0.34 0.00 0.18
2014-12-31 -0.45 0.00 0.21
2014-09-30 0.78 0.00 1.03
2014-06-30 0.53 0.00 0.53
2014-03-31 -0.18 0.00
2013-12-31 -0.18 0.00
  • Emerald Bioscience's level of debt (70.6%) compared to net worth is high (greater than 40%).
  • Unable to establish if Emerald Bioscience's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Emerald Bioscience's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Emerald Bioscience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Emerald Bioscience has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Emerald Bioscience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Emerald Bioscience dividends.
If you bought $2,000 of Emerald Bioscience shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Emerald Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Emerald Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:EMBI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Emerald Bioscience has not reported any payouts.
  • Unable to verify if Emerald Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Emerald Bioscience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Emerald Bioscience has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Emerald Bioscience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Emerald Bioscience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Emerald Bioscience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Emerald Bioscience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brian Murphy
COMPENSATION $390,000
AGE 61
TENURE AS CEO 4.6 years
CEO Bio

Dr. Brian S. Murphy, MD, MPH, MBA has been the Chief Executive Officer at Emerald Bioscience Inc. (formerly known as Nemus Bioscience, Inc.)since August 24, 2015 and served as its Chief Medical Officer since October 2014 until August 21, 2019. Dr. Murphy served as Chief Medical Officer of Eiger BioPharmaceuticals, Inc. He has 15 years experience in drug development and evaluation, both from the academic and industry perspective. He served as Chief Medical Officer of Epiphany Biosciences, Inc. Dr. Murphy served as Chief Medical Officer of Valeant Pharmaceuticals International. Prior to joining Valeant, he held a number of management posts at InterMune, Inc., including Vice President of Hepatology Marketing and Medical Director. He served as Medical Director of North America for Hoffmann-LaRoche working on the development of Pegasys for the treatment of chronic hepatitis C. Dr. Murphy is board-certified in internal medicine, having completed his residency and chief residency in internal medicine at Tufts-New England Medical Center in Boston. He went on to complete fellowships in Clinical Medicine & Epidemiology at Massachusetts General Hospital-Harvard Medical School and in medical ethics at Harvard Medical School where his research interests focused on issues of distributive justice in health care. His clinical practice was focused on the treatment of HIV and HCV and examining clinical outcomes and therapies for those diseases. He serves as a reviewer for a variety of professional publications, including the Annals of Internal Medicine. Dr. Murphy was an Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. He is a member of Alpha Omega Alpha, the national honor medical society. He has been a Director at Emerald Bioscience Inc. (formerly known as Nemus Bioscience, Inc.) since August 24, 2015. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

CEO Compensation
  • Brian's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Brian's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Emerald Bioscience management team in years:

1.8
Average Tenure
49
Average Age
  • The average tenure for the Emerald Bioscience management team is less than 2 years, this suggests a new team.
Management Team

Brian Murphy

TITLE
CEO & Director
COMPENSATION
$390K
AGE
61
TENURE
4.6 yrs

Doug Cesario

TITLE
Chief Financial Officer
COMPENSATION
$250K
AGE
43
TENURE
1.8 yrs

Dennis Kim

TITLE
Chief Medical Officer
COMPENSATION
$285K
AGE
49
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Emerald Bioscience board of directors in years:

2.2
Average Tenure
59
Average Age
  • The average tenure for the Emerald Bioscience board of directors is less than 3 years, this suggests a new board.
Board of Directors

Punit Dhillon

TITLE
Independent Chairman of the Board
COMPENSATION
$65K
AGE
39
TENURE
0.3 yrs

Brian Murphy

TITLE
CEO & Director
COMPENSATION
$390K
AGE
61
TENURE
4.6 yrs

Jim Heppell

TITLE
Independent Director
COMPENSATION
$60K
AGE
63
TENURE
2.2 yrs

Mahmoud ElSohly

TITLE
Member of Scientific Advisory Board

Donald Abrams

TITLE
Member of Scientific Advisory Board
TENURE
4.2 yrs

Avtar Dhillon

TITLE
Non-Voting Observer
COMPENSATION
$118K
AGE
57
TENURE
0.3 yrs

Jeffrey Goldberg

TITLE
Ophthalmology Scientific Advisor

Louis Pasquale

TITLE
Ophthalmology Scientific Advisor

Robert Ritch

TITLE
Ophthalmology Scientific Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Emerald Bioscience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Emerald Bioscience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for unmet medical needs worldwide. The company’s lead product candidate is NB1111 for the treatment of glaucoma. Its products pipeline also comprise NB2222 for the treatment of dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3000 for the treatment of methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is headquartered in Long Beach, California.

Details
Name: Emerald Bioscience Inc.
EMBI
Exchange: OTCPK
Founded: 2012
$13,007,750
183,207,747
Website: http://www.emeraldbio.life
Address: Emerald Bioscience Inc.
130 North Marina Drive,
Long Beach,
California, 90803,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK EMBI Common Stock Pink Sheets LLC US USD 05. Nov 2014
Number of employees
Current staff
Staff numbers
4
Emerald Bioscience employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 01:18
End of day share price update: 2020/03/27 00:00
Last earnings filing: 2020/03/23
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.